Articles

Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment...

COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights

Compass Pathways announces CFO transition

Compass Pathways appoints Daphne Karydas to its Board of Directors

Compass Pathways announces publication of first study evaluating potential of AI model to predict ou...

Compass Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthca...

Compass Pathways Announces Second Quarter 2023 Financial Results and Business Highlights

First clinical study results of psilocybin treatment in anorexia nervosa published in Nature Medicin...

Compass Pathways announces publication of positive data from treatment-resistant depression phase 2 ...

Opinion paper calls for clarity on the definition of “psychedelic-assisted therapy” using psiloc...

American Medical Association Releases Language of First New Current Procedural Terminology Code for ...

Compass Pathways Secures Term Loan Facility for Up to $50 Million from Hercules Capital

Compass Pathways key patents upheld by the US Patent and Trademark Office

Celebrating Pride 2023

Compass Pathways’ Co-Founder Ekaterina Malievskaia to Step Down as Chief Innovation Officer

Data demonstrating long-term improvement in depression in cancer patients following single dose of C...

Compass Pathways Announces First Quarter 2023 Financial Results and Business Highlights

American Medical Association to Issue First New Code for Psychedelic Therapies

Talking to a Principal Investigator on our Phase 3 programme

Launching our Diversity Equity and Inclusion (DEI) council

Compass Pathways Announces Fourth Quarter and Year-End 2022 Financial Results and Business Highlight...

Compass’s impact strategy

Celebrating the International Day of Women and Girls in Science

Supporting parents at work

Our holiday traditions and reflections

COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented...

Pursuing passions: on playing Horseball for Great Britain

Celebrating World Quality Week at Compass

Compass Pathways Announces Third Quarter 2022 Financial Results and Business Highlights

Compass Pathways announces publication of phase 2b study of COMP360 psilocybin therapy for treatment...